The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Open accessPublished version of a preprint
Abstract
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Identification of small-molecule GLP-1R agonists in a CHO-GLP-1R cellular assay in the absence or presence of the positive allosteric modulator BETP. (A) Assay concept. Covalent modification of Cys347 in the GLP-1R by BETP lowers the receptor activation barrier,27 enabling the identification of weak agonists. (B–D) Validation of the BETP-sensitized screening assay. (B) BETP potentiates agonist-induced cAMP production of a small molecule (Boc-5) (Figure 2). (C and D) BETP potentiates cAMP production and β-arrestin recruitment, respectively, by peptide 1 (Figure 2) at the human GLP-1R. (E) cAMP curves of a representative small-molecule HTS hit, compound 2 (Figure 2). cAMP data normalized using 100 nM (+BETP) or 1 μM (+DMSO) GLP-1 response (100%), β-arrestin recruitment data normalized using 1 μM GLP-1 (100%). Data represent the mean ± the standard error of the mean (SEM) from two (B, DMSO), three (C and D, BETP), four (C and D, DMSO), six (B, BETP), seven (E, DMSO), or eight (E, BETP) experiments, each performed in duplicate; error bars are within the displayed symbols. Abbreviations: BETP, 4-[3-(benzyloxy)phenyl]-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; cAMP, cyclic adenosine monophosphate; CHO, Chinese hamster ovary; DMSO, dimethyl sulfoxide; GLP-1R, glucagon-like peptide-1 receptor; PAM, positive allosteric modulator.](/paper-figures/08cd37cfcde04068b1ce24ed82d3d910/a-small-molecule-oral-agonist-of-the-human-glucagon-like-peptide-1-receptor-figure-1.jpg)

![Figure 3 Optimization of small molecule 2 culminating in the identification of the clinical candidate danuglipron. (A) Structure of key compounds in the progression of small-molecule HTS hit 2 to clinical candidate danuglipron. Four structural regions were considered in our efforts to improve the GLP-1R agonist activity of 2: the piperidine, the benzyl ether, the 5-fluoro-pyrimidine, and the benzimidazole. (B) Early evidence of activity in the cAMP assay without BETP. An increased level of cAMP acumulation (percent effect relative to 1 μM GLP-1) at a test compound concentration of 20 μM was observed in the absence of BETP as potency (EC50) improved in the presence of BETP. Data from 1882 analogues. (C) Small-molecule agonist activity independent of BETP sensitization. Increased cAMP potency (EC50) was observed in the absence of BETP as potency improved in the presence of BETP (red circles, non-acids; green circles, acid-containing analogues). Dashed line at a 100:1 EC50 ratio (−BETP/+BETP), solid line at a 1:1 ratio. Data from 1884 analogues. (D and E) Candidate selection CHO-GLP-1R cell line with a lower GLP-1R expression level confirms the efficacy-driven nature of small-molecule 5 agonism at the human GLP-1R. Data represent the mean ± SEM. (D) Saturation binding analysis in CHO cells expressing higher (purple squares, SA) and lower (blue circles, CS) human GLP-1R density. Data represent the mean ± SEM from two individual experiments performed in duplicate. (E) Small molecule 5 induced cAMP signaling in the CS cell line (blue circles), as well as in the SA in the presence (red triangles) or absence (purple squares) of BETP. Data represent the mean ± SEM from 81 (SA + BETP), 105 (SA + DMSO), or 87 (CS) independent experiments, each performed in duplicate; error bars are within the displayed symbols. cAMP data normalized using 100 nM (+BETP) or 1 μM (+DMSO) GLP-1 response (100%). Abbreviations: BETP, 4-[3-(benzyloxy)phenyl]-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; cAMP, cyclic adenosine monophosphate; CHO, Chinese hamster ovary; CS, candidate selection; DMSO, dimethyl sulfoxide; EC50, half-maximal effective concentration; GLP-1, glucagon-like peptide-1; GLP-1R, GLP-1 receptor; HTS, high-throughput screening; PAM, positive allosteric modulator; SA, screening assay; SEM, standard error of the mean.](/paper-figures/ccfb1d57559a4672a75fd6719b967367/a-small-molecule-oral-agonist-of-the-human-glucagon-like-peptide-1-receptor-figure-3.jpg)
![Figure 4 Molecular pharmacology of small-molecule GLP-1R agonist danuglipron. (A) cAMP concentration–response curves for exenatide (black inverted triangle), liraglutide (green squares), and danuglipron (blue circles) in the candidate selection cell line. Data represent the mean ± SEM from 14, 12, and 22 individual experiments, respectively, each performed in duplicate. (B) β-Arrestin recruitment concentration–response curves for exenatide (black inverted triangle), liraglutide (green squares), and danuglipron (blue circles). Data represent the mean ± SEM from four, four, and three individual experiments, respectively, each performed in duplicate. (C) GLP-1R agonist-driven receptor internalization assessed using the FAP-tagged human GLP-1R stably expressed in HEK 293 cells. Data represent the mean ± SEM from three independent experiments, each performed in triplicate. (D) Assessment of danuglipron-induced internalization and recycling of a GFP-tagged human GLP-1R (green) in a HEK 293 cell construct (blue nuclear staining) using confocal microscopy (representative images). (E) Competition binding curve for danuglipron using the [3H]PF-06883365 probe. Data represent the mean ± SEM from four individual experiments, each performed in quadruplicate. cAMP, β-arrestin recruitment, and internalization data normalized to a 1 μM GLP-1 response (100%). In the curves, error bars are within the displayed symbols.](/paper-figures/947134bb0bec4f3f91de35b25e38c965/a-small-molecule-oral-agonist-of-the-human-glucagon-like-peptide-1-receptor-figure-4.jpg)
![Figure 5 Binding affinity of danuglipron, as evaluated using a competition binding assay based on radiolabeled small-molecule agonist [3H]PF-06883365. (A) Structure of the small-molecule agonist radioligand [3H]PF-06883365. (B) Saturation binding analysis for [3H]PF-06883365 showed that [3H]PF-06883365 binds plasma membranes from CHO cells stably expressing a high density of the hGLP-1R (“binding cell line”) with an averaged Kd of 38 nM and a Bmax of 5470 fmol/mg. Data represent the mean ± SEM from two independent experiments, each performed in quadruplicate; error bars are within the displayed symbols.](/paper-figures/eb9f8de4ce6947ae94b090b382446483/a-small-molecule-oral-agonist-of-the-human-glucagon-like-peptide-1-receptor-figure-5.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Danuglipron is another oral, non-peptide, G-protein biased GLP-1 RA [26].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Danuglipron is another orally administered, non-peptide GLP-1 receptor agonist oriented towards G-protein [110].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome Biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,157
Gctf: Real-time CTF determination and correction
Zhang, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.11.003 · Cited by 3,537
Real-space refinement in PHENIX for cryo-EM and crystallography
Afonine, P. V., Poon, B. K., Read, R. J., Sobolev, O. V., Terwilliger, T. C., Urzhumtsev, A., & Adams, P. D. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318006551 · Cited by 3,281
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Cited by
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
Self-citationSaxena, A. R., Frias, J. P., Brown, L. S., Gorman, D. N., Vasas, S., Tsamandouras, N., & Birnbaum, M. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14493 · Cited by 149
Self-citationPratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15184 · Cited by 62
Metadata
- Authors
- Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., Derksen, D. R., Dias, J. M., Griffor, M. C., Han, S., Jackson, V. M., Landis, M. S., Lettiere, D., Limberakis, C., Liu, Y., Mathiowetz, A. M., Patel, J. C., Piotrowski, D. W., Price, D. A., Ruggeri, R. B., & Tess, D. A.
- Affiliations
- Pfizer (United States) (US)
- Sosei Heptares, Cambridge CB21 6DG, U.K.
- Corresponding author
- Griffith, David A.
- ORCID
- Griffith, David A.
- Edmonds, David J.
- Kalgutkar, Amit S.
- Kuzmiski, J. Brent
- Loria, Paula M.
- Saxena, Aditi R.
- Bagley, Scott W.
- Buckeridge, Clare
- Curto, John M.
- Dias, João M.
- Griffor, Matthew C.
- Han, Seungil
- Jackson, V. Margaret
- Landis, Margaret S.
- Lettiere, Daniel
- Limberakis, Chris
- Liu, Yuhang
- Piotrowski, David W.
- Ruggeri, Roger B.
- Tess, David A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-06-01
- Volume
- 65
- Issue
- 12
- Pages
- 8208-8226
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC9234956
- OpenAlex
- W4281627591
- Cited by
- 192
- References
- 59
- Citations by year
- 2026: 42 · 2025: 58 · 2024: 40 · 2023: 33 · 2022: 7
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- GLP-1 receptor, oral bioavailability, small molecule drug discovery, receptor mutagenesis, cryo-EM structure, insulin secretion, metabolic clearance, diabetes treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Humans, Hypoglycemic Agents, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01856
- The paper
- Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., Derksen, D. R., Dias, J. M., Griffor, M. C., Han, S., Jackson, V. M., Landis, M. S., Lettiere, D., Limberakis, C., Liu, Y., . . . Tess, D. A. (2022). A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.